In September 2023, Charles River Laboratories announced a multi-program collaboration agreement with Related Sciences, including high-throughput screening, medicinal chemistry, ADME, biology, pharmacology and ultimately, safety testing and IND submission.
In June 2023, BioIVT hosted an advanced in vitro ADME strategies symposium in Copenhagen.
Thermo Fisher Scientific, a global leader in scientific research and services, introduced a high-throughput in vitro ADME toxicology testing platform (in September 2022). This platform enabled faster and more efficient screening of drug candidates. It helped researchers identify potential toxic effects earlier in the drug development process.
In May 2022, An Asia Pacific launch of Charles River Laboratories’ ADME toxicology testing services happened. The main objective was meeting the demand for drug safety assessment that is fast rising in this area and providing support to pharmaceutical industries as they develop their drugs.
The expansion is part of the recent increase by Eurofins Discovery into its ADME toxicology testing capabilities reported at the beginning of January 2022. For instance, new in vitro models have been incorporated by the company for more accurate and efficient toxicology evaluation.
While excluding Sweden’s market, Thermo Fisher ScientificTM will be able to launch ASTar
In September 2022 exclusively throughout all geographies except one. The partnership is also exclusive to rapid AST testing between both companies. They will work closely together, creating an inclusive AST portfolio for our clients.
In January 2020, Thermofisher Scientific introduced its next-generation compressor-free plate sealer that requires minimal operator maintenance but still provides unmatched levels of customization flexibility during operation as well as significant workflow improvements. For biotech, pharma or academic research laboratory users alike who now have access to technology that streamlines plate sealing while boosting throughput on both standalone projects or integrated robotic systems.
The ADME Toxicology Testing Market is segmented on the basis of method, technology, application, and end-user.
The Market, by method is categorised into cellular assay, biochemical assay, in silica, and ex-vivo.
The technology segment is categorised into cell culture, high throughput, molecular imaging, and OMICS technology.
On the basis of application, the ADME Toxicology Testing Market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centres, pathological labs, and others.
On the basis of region, the global ADME Toxicology Testing Market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
It is projected that the Americas dominated the global ADME toxicology testing market owing to the growth in the North America region which is largely attributed to the factors such as increase in research funding, growing awareness on the benefits of ADME toxicology testing for commercial industries, and high adoption of toxicology testing in research. These factors have cumulatively influenced the growth of the market in this regionEurope stood second largest in the ADME toxicology testing market owing to high acceptance of toxicology testing in research. Additionally, development in research expenditure was also responsible for the development of market. Moreover, in January 2014, Cyprotex PLC, a UK based company signed an acquisition agreement with CeeTox, Inc. for its business. The company intended to expand its portfolio for in-vitro toxicity assays and screening services to the Cosmetics and Personal Care Industry.
Asia-Pacific was projected to be the fastest growing region for the global ADME toxicology testing market in 2017. The factors attributed to the due to increased efforts for development of new diagnostic devices and adoption of newer technologies to improve the standard of diagnostics assays being supplied. China and Japan are key countries contributing to market growth.The Middle East and Africa holds the least share in the global ADME toxicology testing market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing toxicology care programs in the Middle East.
Global ADME toxicology testing Global Market, by Key Players:
Recent Development
Intended Audience:
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â USDÂ 3.02 Billion |
| Â Â CAGR | Â Â 12.1% |
| Â Â Base Year | Â Â 2021 |
| Â Â Forecast Period | Â Â 2023-2032 |
| Â Â Historical Data | Â Â 2020 |
| Â Â Forecast Units | Â Â Value (USD Million) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Method, Technology, Application, and End-user |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Promega Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Accelrys, Inc., Molecular Discovery Ltd., Cyprotex PLC, MultiCASE, Inc., Caliper Life Sciences, Inc., Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., CeeTox, Inc., and others. |
|   Key Market Opportunities | · Increase in research funding · Growing awareness on the benefits of ADME toxicology testing for commercial industries · High adoption of toxicology testing in research |
|   Key Market Drivers | · Rising application of ADME toxicology testing by pharmaceuticals and biotechnology companies · Growing concerns over application of animals in clinical trials |
ADME Toxicology Testing Market Highlights:
Frequently Asked Questions (FAQ) :
The ADME Toxicology Testing Market is expected to register a CAGR of 12.1% during forecast period upto 2032.
The Growing concerns over application of animals in clinical trials is the major driving factor of ADME Toxicology Testing Market.
Promega Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Cellartis AB, Cyprotex PLC., Life Technologies Corporation, Optivia Biotechnology, Inc., Accelrys, Inc., Molecular Discovery Ltd., Cyprotex PLC, MultiCASE, Inc., Caliper Life Sciences, Inc., Xceleron, Inc., ACEA Biosciences, Inc., Albany Molecular Research, Inc., CeeTox, Inc., and others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
